JP2003519096A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003519096A5 JP2003519096A5 JP2001516562A JP2001516562A JP2003519096A5 JP 2003519096 A5 JP2003519096 A5 JP 2003519096A5 JP 2001516562 A JP2001516562 A JP 2001516562A JP 2001516562 A JP2001516562 A JP 2001516562A JP 2003519096 A5 JP2003519096 A5 JP 2003519096A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- binding agent
- mammal
- administered
- therapeutic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000011230 binding agent Substances 0.000 description 35
- 206010028980 Neoplasm Diseases 0.000 description 34
- 238000000034 method Methods 0.000 description 26
- 241000124008 Mammalia Species 0.000 description 24
- 102100034256 Mucin-1 Human genes 0.000 description 17
- 108010008707 Mucin-1 Proteins 0.000 description 17
- 230000001225 therapeutic effect Effects 0.000 description 16
- 230000037396 body weight Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- VANSZAOQCMTTPB-SETSBSEESA-N hypocrellin Chemical compound C1[C@@](C)(O)[C@@H](C(C)=O)C2=C(OC)C(O)=C3C(=O)C=C(OC)C4=C3C2=C2C3=C4C(OC)=CC(=O)C3=C(O)C(OC)=C21 VANSZAOQCMTTPB-SETSBSEESA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
- 241000342334 Human metapneumovirus Species 0.000 description 1
- KGHNSNSWRMJVND-UHFFFAOYSA-N Hypocrellin Natural products COC1=CC(=O)C2=C3C4C(C(C(=O)C)C(C)(O)Cc5c(OC)c(O)c6C(=O)C=C(OC)C(=C13)c6c45)C(=C2O)OC KGHNSNSWRMJVND-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 108010017838 cyclo-(lysyl-prolyl-glycyl-prolyl-glycyl-glutamyl-prolyl-glycyl-prolyl-glycyl)cyclo(1epsilon-6gamma)glycyl-glycine Proteins 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- BQJKVFXDDMQLBE-UHFFFAOYSA-N shiraiachrome A Natural products COC1=C2C3=C(OC)C=C(O)C4=C3C3=C5C(CC(C)(O)C(C(C)=O)C3=C(OC)C4=O)=C(OC)C(=O)C(C(O)=C1)=C25 BQJKVFXDDMQLBE-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14949299P | 1999-08-18 | 1999-08-18 | |
| US60/149,492 | 1999-08-18 | ||
| US16471499P | 1999-11-11 | 1999-11-11 | |
| US60/164,714 | 1999-11-11 | ||
| PCT/US2000/022890 WO2001012217A1 (en) | 1999-08-18 | 2000-08-18 | Therapeutic antibody against muc-1 antigen and methods for their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011193430A Division JP2012046518A (ja) | 1999-08-18 | 2011-09-06 | Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003519096A JP2003519096A (ja) | 2003-06-17 |
| JP2003519096A5 true JP2003519096A5 (enExample) | 2007-09-27 |
Family
ID=26846783
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001516562A Withdrawn JP2003519096A (ja) | 1999-08-18 | 2000-08-18 | Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法 |
| JP2011193430A Pending JP2012046518A (ja) | 1999-08-18 | 2011-09-06 | Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011193430A Pending JP2012046518A (ja) | 1999-08-18 | 2011-09-06 | Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1204423B1 (enExample) |
| JP (2) | JP2003519096A (enExample) |
| AT (1) | ATE290879T1 (enExample) |
| AU (1) | AU782569B2 (enExample) |
| DE (1) | DE60018761T2 (enExample) |
| ES (1) | ES2239032T3 (enExample) |
| WO (1) | WO2001012217A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8038994B2 (en) | 1996-05-15 | 2011-10-18 | Quest Pharmatech Inc. | Combination therapy for treating disease |
| WO2002058450A2 (en) | 2000-12-22 | 2002-08-01 | Dana-Faber Cancer Institute, Inc. | Regulation of cell growth by muc1 |
| US20040110846A1 (en) * | 2001-01-30 | 2004-06-10 | Beatrice Leveugle | Perylenequinones for use with immunotherapy agents |
| US6627664B2 (en) * | 2001-01-30 | 2003-09-30 | Altachem Pharma Ltd. | Perylenequinones for use as sonosensitizers |
| US8198400B2 (en) | 2001-03-27 | 2012-06-12 | Oncothyreon, Inc. | Vaccine for modulating between T1 and T2 immune responses |
| CH696871A5 (de) * | 2001-10-26 | 2008-01-15 | Altarex Medical Corp | Verwendung eines chemotherapeutischen Arzneimittels und einer Zusammensetzung, die ein Bindemittel umfasst, zur Herstellung eines Medikamentes zur Krankheitsbehandlung. |
| TR200401834T2 (tr) * | 2002-01-24 | 2005-10-21 | Barnes-Jewish Hospital | İntegrin hedefli görüntüleme etken maddeleri. |
| DE10256900A1 (de) | 2002-11-29 | 2004-06-24 | Nemod Immuntherapie Ag | Tumorspezifische Erkennungsmoleküle |
| DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| US8129506B2 (en) | 2003-10-24 | 2012-03-06 | Genzyme Corporation | Modulation of the interaction of MUC1 with MUC1 ligands |
| TWI395591B (zh) | 2004-04-01 | 2013-05-11 | Oncothyreon Inc | 黏液性糖蛋白（ｍｕｃ-１）疫苗 |
| EP1848804B1 (en) * | 2005-01-28 | 2011-10-05 | Ramot at Tel Aviv University, Ltd. | Anti-muc1 alpha beta antibodies |
| ES2526344T3 (es) | 2005-06-28 | 2015-01-09 | Oncothyreon Inc. | Método para el tratamiento de pacientes con una vacuna de glicoproteína mucinosa (MUC-1) |
| AU2006279189B2 (en) | 2005-08-10 | 2011-08-04 | Quest Pharmatech Inc. | Perylenequinone derivatives and uses thereof |
| US8454991B2 (en) | 2006-07-24 | 2013-06-04 | Quest Pharmatech Inc. | Method and device for photodynamic therapy |
| HRP20150307T1 (hr) | 2006-09-10 | 2015-04-24 | Glycotope Gmbh | Upotreba ljudskih stanica podrijetlom iz ljudske leukemije za eksprimiranje protutijela |
| EP1920781B1 (en) | 2006-11-10 | 2015-03-04 | Glycotope GmbH | Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors |
| WO2008097844A2 (en) | 2007-02-02 | 2008-08-14 | Dana -Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins |
| US7972870B2 (en) | 2007-02-02 | 2011-07-05 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3 |
| CN102264765B (zh) | 2008-10-28 | 2016-01-20 | 盐野义制药株式会社 | 抗muc1抗体 |
| EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| EP2565268A4 (en) | 2010-04-28 | 2013-10-09 | Shionogi & Co | NEW MUC1 ANTIBODY |
| KR20140023903A (ko) | 2011-02-24 | 2014-02-27 | 온코타이레온, 인코포레이티드 | 항원보강제를 갖는 muc1 기초 당지질펩티드 백신 |
| BR112014004065A2 (pt) | 2011-08-22 | 2017-03-14 | Glycotope Gmbh | micro-organismos carregando um antígeno de tumor |
| JP2017009287A (ja) * | 2013-11-11 | 2017-01-12 | 東ソー株式会社 | 前立腺癌と前立腺肥大症との識別方法 |
| AU2015254257B2 (en) | 2014-04-28 | 2021-02-25 | Medicinal Chemistry Pharmaceuticals, Co., Ltd. | Anti-MUC1 antibody or antigen-binding fragment of same, and use thereof |
| CA3050039A1 (en) * | 2017-01-27 | 2018-08-02 | Glycotope Gmbh | Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor |
| BR112020023373A2 (pt) | 2018-05-18 | 2021-02-09 | Daiichi Sankyo Company, Limited | conjugado, composição, e, uso de um conjugado ou de uma composição |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3698370B2 (ja) * | 1992-04-13 | 2005-09-21 | ダナ−ファーバー キャンサー インスティチュート インク | 癌腫抗原用抗体 |
| JPH08505119A (ja) * | 1992-07-06 | 1996-06-04 | バイオミラ、インコーポレーテッド | 接合目的のためのタンパク質の光活性化 |
| AU5615594A (en) * | 1992-11-13 | 1994-06-08 | Cancer Research Fund Of Contra Costa | Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods |
| DE19534630A1 (de) * | 1995-09-18 | 1997-03-20 | Max Delbrueck Centrum | Monoklonale Antikörper gegen epitheliales Muzin (MUC1) |
| NZ505174A (en) * | 1996-05-15 | 2002-03-01 | Altarex Inc | Cancer antigens CA125 (multiple epitote) recognised by OC125, M11, B43.13, B27.1, where B43.13 is used as a binding agent to elicit host immune response as a vaccination method against cancer |
| WO1998033470A2 (en) * | 1997-01-10 | 1998-08-06 | Altarex Corp. | Substituted perylenequinones for use in photodynamic therapy |
| JP2002502621A (ja) * | 1998-02-13 | 2002-01-29 | バステルト・ギュンター | 乳腫瘍を伴うムチンに対する特異性のある抗体、その生産方法及び使用方法 |
-
2000
- 2000-08-18 JP JP2001516562A patent/JP2003519096A/ja not_active Withdrawn
- 2000-08-18 AT AT00957617T patent/ATE290879T1/de active IP Right Revival
- 2000-08-18 EP EP00957617A patent/EP1204423B1/en not_active Expired - Lifetime
- 2000-08-18 DE DE60018761T patent/DE60018761T2/de not_active Expired - Lifetime
- 2000-08-18 AU AU69211/00A patent/AU782569B2/en not_active Ceased
- 2000-08-18 WO PCT/US2000/022890 patent/WO2001012217A1/en not_active Ceased
- 2000-08-18 ES ES00957617T patent/ES2239032T3/es not_active Expired - Lifetime
-
2011
- 2011-09-06 JP JP2011193430A patent/JP2012046518A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003519096A5 (enExample) | ||
| Mew et al. | Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. | |
| EP3151865B1 (en) | Site-specific conjugation of linker drugs to antibodies and resulting adcs | |
| JP2021102648A (ja) | 抗ｆｏｌｒ１免疫複合体投与計画 | |
| Blumenthal et al. | Comparison of therapeutic efficacy and host toxicity of two different 131I‐labelled antibodies and their fragments in the GW‐39 colonic cancer xenograft model | |
| US20090192071A1 (en) | Use of photodynamic therapy to enhance treatment with immuno-modulating agents | |
| WO2002100326A3 (en) | Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies | |
| JP2005517674A (ja) | 腫瘍の処置に有用な新規免疫コンジュゲート | |
| MXPA02010059A (es) | Metodo para administrar un anticuerpo. | |
| PT910407E (pt) | Metodo e composicao para modificar a conformacao de antigenios multi-epitopicos de modo a iniciar uma resposta imunitaria | |
| CN101969980A (zh) | 抗-EDb纤连蛋白抗体-IL-2融合蛋白与结合至B细胞、B祖细胞和/或它们的癌性对应物的分子的组合物 | |
| US6022541A (en) | Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel | |
| Remsen et al. | Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model | |
| Punyakoti et al. | Postulating the possible cellular signalling mechanisms of antibody drug conjugates in Alzheimer's disease | |
| JPS63238023A (ja) | 抗腫瘍イムノトキシン及び腫瘍壊死因子を含んで成る医薬 | |
| JPH10508868A (ja) | ＴＰ−３／ｐ８０を標的とする癌の生物療法 | |
| US5151266A (en) | Use of anionic detergents with conjugates of monoclonal or polyclonal antibodies | |
| Schulz et al. | Immunotherapy of pancreatic cancer with monoclonal antibody BW 494 | |
| EP0213881B1 (en) | The use of amphipathic molecules for radioimaging and therapy with conjugates of monoclonal or polyclonal antibodies | |
| Lee et al. | Antibodies as specific carriers for chemotherapeutic agents | |
| WO2002087611A2 (de) | Mittel humanen ursprungs zur vakzination gegen gd2-positive tumore | |
| Büchler et al. | Studies of pancreatic cancer utilizing monoclonal antibodies | |
| WO1994023753A1 (en) | Cancer therapy, using antibody conjugates, in combination with a vasoactive agent | |
| JP3676915B2 (ja) | 雑種細胞の注射による腫瘍免疫の誘導 | |
| Wang et al. | Enhancement of the Antitumor Effect of γ-Ray Irradiation in Combination with Camptothecin against Human Colorectal Adenocarcinoma |